A3 receptor agonist modulates IL-1ß hippocampus levels in a rat model of neuropathic pain

Introduction: Considering the lack of specific treatments for neuropathic pain, this study aimed to evaluate the effect of a single dose of adenosine A3 receptor IB-MECA on inflammatory and neurotrophic parameters in rats subjected to a neuropathic pain model. Methods: 64 adult male Wistar rats were used. Neuropathic pain was induced by chronic constriction injury (CCI) of the sciatic nerve and the treatment consisted of a 0.5 µmol/kg dose of IB-MECA, a selective A3 adenosine receptor agonist, dissolved in 3% DMSO; vehicle groups received DMSO 3% in saline solution, and morphine groups received 5 mg/kg. Cerebral cortex and hippocampus IL-1ß, BDNF, and NGF levels were determined by Enzyme-Linked Immunosorbent assay. Results: The main outcome was that a single dose of IB-MECA was able to modulate the IL-1ß hippocampal levels in neuropathic pain induced by CCI and the DMSO increased IL-1ß and NGF hippocampal levels in sham-operated rats. However, we did not observe this effect when the DMSO was used as vehicle for IB-MECA, indicating that IB-MECA was able to prevent the effect of DMSO. Conclusions: Considering that the IL-1ß role in neuropathic pain and the contributions of the hippocampus are well explored, our result corroborates the relationship between the A3 receptor and the process of chronic pain maintenance.

Dolor neuropático localizado / Localized neuropathic pain

Resumen El dolor neuropático localizado (DNL) es de origen periférico y se caracteriza por áreas circunscritas de dolor con sensibilidad anormal de la piel o síntomas espontáneos característicos de dolor neuropático, por ejemplo, dolor urente. Se debe resaltar que el DNL está confinado a un área específica no mayor a una hoja de papel tamaño carta. El DNL representa 60 % de las condiciones de dolor neuropático. No existe una única etiología. El abordaje diagnóstico es similar al de otros síndromes dolorosos neuropáticos. Se utilizan herramientas diagnósticas generales para evaluar las características clínicas. En la actualidad no existen guías específicas de manejo del DNL, por lo que se utilizan las guías para dolor neuropático en general. En las guías de la Sociedad Canadiense de Dolor se incluyen los tratamientos tópicos como parte de las estrategias de segunda línea. Pese a la falta de guías, los parches de lidocaína a 5 % y los parches de capsaicina a 8 % han demostrado ser efectivos en modelos de DNL.

Abstract Localized neuropathic pain (LNP) is of peripheral origin and is characterized by circumscribed areas of pain with abnormal skin sensitivity or spontaneous symptoms that are characteristic of neuropathic pain, e.g. burning pain. It should be noted that LNP is confined to a specific area no larger than a letter size sheet of paper. LNP accounts for 60 % of neuropathic pain conditions. There is no single etiology of LNP. The diagnostic approach is similar to that for other neuropathic pain syndromes. General diagnostic tools are used to assess clinical features. So far, there are no specific guidelines for the management of LNP; for this reason, guidelines for general neuropathic pain are used. Topical treatments are included as part of second-line strategies in the Canadian Pain Society guidelines. Despite the lack of guidelines, 5 % lidocaine patches and 8 % capsaicin patches have been proven effective in LNP models.

Neurectomy of C2 for the Treatment of Occipital Neuralgia: Case Report

Occipital neuralgia (ON) is an uncommon cause of headache, and it is characterized by a stabbing paroxysmal pain that radiates to the occipital region. The present study includes a review of the literature and a case report. The etiology of this pathology can vary from traumas, infections, compressions of nerves or vertebrae, skull base surgeries, to degenerative changes and congenital anomalies. However, most of the time, the etiology is considered idiopathic. The diagnosis is essentially clinical. However, it is crucial that other types of primary headache are excluded. The treatment for ON may be based on nerve blocks, medications or surgeries. Neurectomy of the second spinal nerve is among the surgical techniques available.

Consenso multidisciplinario de diagnóstico y tratamiento del dolor neuropático periférico y localizado en México / Multidisciplinary consensus on diagnosis and treatment of peripheral and localized neuropathic pain in Mexico

Resumen El dolor neuropático es una entidad que provoca discapacidad al paciente y su diagnóstico y tratamiento es un reto para los médicos. En un porcentaje importante de pacientes afectados, el dolor neuropático se presenta circunscrito a un dermatoma o a una región concreta del cuerpo, denominándose en ese caso dolor neuropático localizado. No existen guías clínicas mexicanas que postulen recomendaciones para el diagnóstico y tratamiento del dolor neuropático localizado en nuestra población. En este artículo se exponen las recomendaciones de un consenso multidisciplinario realizado con especialistas de distintas áreas implicadas en el diagnóstico y tratamiento de este tipo de pacientes.

Abstract Neuropathic pain is an entity that causes patient disability and its diagnosis and treatment is a challenge for physicians. In a significant percentage of patients with neuropathic pain, it is restricted to one dermatome or to a particular region of the body; in this case, it is referred to as localized neuropathic pain. There are no Mexican clinical guidelines proposing recommendations for the diagnosis and treatment of localized neuropathic pain in our population. This article presents the recommendations of a multidisciplinary consensus of specialists from different areas involved in the diagnosis and treatment of this type of patients.

Neuralgia occipital: relato de caso e revisão / Occipital Neuralgia: Case Report and Review

Neuralgia occipital (NO) é uma causa incomum de cefaleia caracterizada por dor paroxística, do tipo pontada, que se irradia para a região occipital. O objetivo deste artigo é relatar o caso de uma paciente com NO e descrever a técnica cirúrgica utilizada. O estudo compreende um levantamento bibliográfico para o conhecimento e melhor abordagem sobre o assunto. Com base na literatura, observa-se que a etiologia pode variar desde traumas, infecções, cirurgias de base de crânio, compressões de nervos ou vértebras até alterações degenerativas e anomalias congênitas. Porém, em sua maioria, os casos são idiopáticos. Apesar de o diagnóstico ser essencialmente clínico, é fundamental que sejam excluídos outros tipos de cefaleias primárias. De acordo com a gravidade e o tempo de evolução do caso, o tratamento da NO pode basear-se em bloqueios nervosos, medicamentos ­ como anti-inflamatórios não-esteroides e relaxantes musculares ­ ou cirurgias. Entre os procedimentos cirúrgicos disponíveis, encontram-se a descompressão do nervo occipital maior, ablação por radiofrequência e implantação de neuroestimulador.

Occipital Neuralgia (ON) is an uncommon cause of headache, characterized by paroxysmal pain, stabbing that radiates to occipital region. This article aims at reviewing the literature to the approach to the subject and performs the case report of patient who present with ON and underwent a surgical treatment. Based on the literature and analysis showed the etiologymay vary from trauma, infections, skull base surgery, compression of nerves or vertebrae to degenerative changes and congenital anomalies. However, most cases are idiopathic. Although the diagnosis is essentially clinical, it is essential that other types of primary headaches are excluded. According to severity and the time course of the case, the treatment of ON may be based on nerve blocks, medications like non-steroidal anti-inflammatory drugs and muscle relaxants. Surgical treatment for ON are nerve decompression, pulsed radiofrequency ablation and stimulator implantation.

Translation and transcultural adaptation of Pain Quality Assessment Scale (PQAS) to brazilian version / Tradução e adaptação transcultural da Pain Quality Assessment Scale (PQAS) para a versão brasileira

INTRODUCTION: Most cancer patients are treated with chemotherapy, and peripheral neuropathy is a serious and common clinical problem affecting patients undergoing cancer treatment. However, the symptoms are subjective and underdiagnosed by health professionals. Thus, it becomes necessary to develop self-report instruments to overcome this limitation and improve the patient's perception about his medical condition or treatment. OBJECTIVE: Translate and culturally adapt the Brazilian version of the Pain Quality Assessment Scale, constituting a useful tool for assessing the quality of neuropathic pain in cancer patients. METHOD: The procedure followed the steps of translation, back translation, analysis of Portuguese and English versions by a committee of judges, and pretest. Pretest was conducted with 30 cancer patients undergoing chemotherapy following internationally recommended standards, and the final versions were compared and evaluated by a committee of researchers from Brazil and MAPI Research Trust, the scale's creators. RESULTS: Versions one and two showed 100% semantic equivalence with the original version. Back-translation showed difference between the linguistic translation and the original version. After evaluation by the committee of judges, a flaw was found in the empirical equivalence and idiomatic equivalence. In pretest, two people did not understand the item 12 of the scale, without interfering in the final elaboration. CONCLUSION: The translated and culturally adapted instrument is now presented in this publication, and currently it is in the process of clinical validation in Brazil.

INTRODUÇÃO: a maioria dos pacientes com câncer são tratados com quimioterápicos e a neuropatia periférica é um problema clínico sério e comum que afeta os pacientes em tratamento oncológico. Entretanto, tais sintomas são subjetivos sendo subdiagnosticado pelos profissionais de saúde. Assim, torna-se necessário o desenvolvimento de instrumentos de autorrelato para superar essa limitação e melhorar a percepção do paciente sobre o seu tratamento ou condição clínica. OBJETIVO: traduzir e adaptar transculturalmente a versão brasileira do Pain Quality Assessment Scale (PQAS), constituindo em um instrumento útil de avaliação da qualidade da dor neuropática em pacientes com câncer. MÉTODO: o procedimento seguiu as etapas de tradução, retrotradução, análise das versões português e inglês por um comitê de juízes e pré-teste. O pré-teste foi realizado em 30 pacientes com câncer em tratamento quimioterápico seguindo normas internacionalmente recomendadas, sendo as versões finais comparadas e avaliadas por comitê de pesquisadores brasileiros e da MAPI Research Trust, originadores da escala. RESULTADOS: as versões um e dois apresentaram 100% de equivalência semântica com a versão original. Na retrotradução houve diferenças na tradução linguística com a versão original. Após a avaliação do Comitê de Juízes, foi encontrada uma falha na equivalência empírica e na equivalência idiomática. No pré-teste, duas pessoas não entenderam o item 12 da escala, sem interferir na elaboração final da mesma. CONCLUSÃO: o instrumento agora traduzido e adaptado transculturalmente é apresentado nessa publicação e, atualmente, encontra-se em processo de validação clínica no Brasil.

Diagnosis and medical treatment of neuropathic pain in leprosy / Diagnóstico e tratamento medicamentoso da dor neuropática em hanseníase / Diagnóstico y tratamiento medicamentoso del dolor neuropático en la lepra

ABSTRACT Objective: to identify the difficulties in diagnosing and treating neuropathic pain caused by leprosy and to understand the main characteristics of this situation. Methods: 85 patients were treated in outpatient units with reference to leprosy and the accompanying pain. We used a questionnaire known as the Douleur Neuropathic 4 test and we conducted detailed neurological exams. As a result, 42 patients were excluded from the study for not having proved their pain. Results: Out of the 37 patients that experienced pain, 22 (59.5%) had neuropathic pain (or a mixture of this pain and their existing pain) and of these 90.8% considered this pain to be moderate or severe. 81.8% of the sample suffered with this pain for more than 6 months. Only 12 (54.5%) of the patients had been diagnosed with neuropathic pain and in almost half of these cases, this pain had not been diagnosed. With reference to medical treatment (n=12) for neuropathic pain, 5 (41.6%) responded that they became better. For the other 7 (58.4%) there were no changes in relation to the pain or in some cases the pain worsened in comparison to their previous state. Statistical analysis comparing improvements in relation to the pain amongst the patients that were treated (n=12) and those that were not, showed significant differences (value p=0.020). Conclusion: we noted difficulties in diagnosing neuropathic pain for leprosy in that almost half of the patients that were studied had not had their pain diagnosed. We attributed this to some factors such as the non-adoption of the appropriate protocols which led to inadequate diagnosis and treatment that overlooked the true picture.

RESUMO Objetivo: identificar as dificuldades em diagnosticar e tratar a dor neuropática causada pela hanseníase, bem como determinar as características principais dessa situação. Métodos: examinaram-se 85 pacientes tratados no ambulatório de referência para hanseníase e referiam dor. Aplicou-se questionário, o teste Douleur Neuropathic 4, e criterioso exame neurológico pelo qual excluíram-se 42 pacientes por não se comprovar dor. Resultados: dos 37 pacientes com dor, 22 (59,5%) tinham Douleur Neuropathic ou mista e, desses, 90,8% caracterizavam essa dor como de intensidade moderada ou severa, sendo que 81,8% sofriam por mais de 6 meses. Apenas 12 (54,5%) pacientes haviam sido diagnosticados com Douleur Neuropathic e quase metade dos casos (45,5%) estava sem reconhecimento. Quanto ao tratamento medicamentoso (n=12) para a Douleur Neuropathic, 5 (41,6%) responderam que tiveram melhora, nos outros 7 (58,4%) não houve alteração da dor ou pioraram quando se comparou ao quadro inicial. A análise estatística, comparando a melhora da dor entre os pacientes tratados (n=12) e aqueles não tratados (n=10), foi significante (valor-p=0,020). Conclusão: identificou-se dificuldade em diagnosticar a dor neuropática em hanseníase, haja vista que quase metade dos pacientes estudados estava sem reconhecimento desse quadro. Atribuíram-se, como fatores associados, a não adoção de protocolo apropriado para efetivo diagnóstico e tratamentos inadequados que podem mascarar o quadro.

RESUMEN Objetivo: identificar las dificultades de diagnosticar y tratar el dolor neuropático causado por la lepra, así como determinar las características principales de esa situación. Métodos: se examinaron 85 pacientes tratados en ambulatorio de referencia para lepra y que refirieron dolor. Se aplicó el cuestionario test Douleur Neuropathic 4, y se hizo un minucioso examen neurológico a través del cual se excluyeron 42 pacientes por no haberse comprobado dolor. Resultados: de los 37 pacientes con dolor, 22 (59,5%) tenían dolor neuropático o mixto y, de esos, 90,8% caracterizaban ese dolor como de intensidad moderada o severa, siendo que 81,8% sufrían de él hace más de 6 meses. Apenas 12 (54,5%) pacientes habían sido diagnosticados con dolor neuropático y casi mitad de los casos (45,5%) estaba sin reconocimiento. En cuanto al tratamiento medicamentoso (n=12) para el dolor neuropático, 5 (41,6%) respondieron que tuvieron mejoría; en los otros 7 (58,4%) no hubo alteración del dolor o empeoraron cuando se comparó con el cuadro inicial. El análisis estadístico, comparando la mejoría del dolor entre los pacientes tratados (n=12) y aquellos no tratados (n=10), fue significativa (valor-p=0,020). Conclusión: se identificó dificultad en diagnosticar el dolor neuropático en la lepra, considerando que casi la mitad de los pacientes estudiados estaban sin reconocimiento de ese cuadro. Se atribuyeron como factores asociados la no adopción de protocolo apropiado para un efectivo diagnóstico y tratamientos inadecuados que pudieron haber enmascarar el cuadro.

Validation of the Korean Version of the DN4 Diagnostic Questionnaire for Neuropathic Pain in Patients with Lumbar or Lumbar-Radicular Pain

PURPOSE: To evaluate the diagnostic value of the Korean version of the Douleur Neuropathique 4 (DN4) questionnaire and to validate this questionnaire in terms of psychometric properties in patients with chronic pain due to degenerative spinal disease. MATERIALS AND METHODS: The Korean version of the DN4 questionnaire, which was translated and linguistically validated by the MAPI Research Group, was tested on 83 patients with lumbar or lumbar-radicular pain. Test-retest reliability was evaluated in a subsample of 40 patients who completed two assessments with an interval of 2 weeks. Nociceptive pain and neuropathic component pain were diagnosed in 40 and 43 patients, respectively. RESULTS: The Cronbach's alpha coefficient of internal consistency was 0.819, and the test-retest intraclass correlation coefficient (3, 1) (95% confidence interval) was 0.813 (0.776-0.847) (n=40). The area under the receiver-operator characteristics curve was 0.953 (p<0.001), with 95% confidence interval between 0.869 and 0.990. The Korean version of the DN4 questionnaire showed a sensitivity of 100% and 87.1%, and a specificity of 88.2% and 94.1% at the cutoff value of 3/10 and 4/10, respectively, for discriminating neuropathic component pain. CONCLUSION: The present study demonstrated the good discriminatory power of DN4 between nociceptive pain and neuropathic component pain in patients with lumbar or lumbar-radicular pain.

Neuralgias of the Head: Occipital Neuralgia

Occipital neuralgia is defined by the International Headache Society as paroxysmal shooting or stabbing pain in the dermatomes of the greater or lesser occipital nerve. Various treatment methods exist, from medical treatment to open surgical procedures. Local injection with corticosteroid can improve symptoms, though generally only temporarily. More invasive procedures can be considered for cases that do not respond adequately to medical therapies or repeated injections. Radiofrequency lesioning of the greater occipital nerve can relieve symptoms, but there is a tendency for the pain to recur during follow-up. There also remains a substantial group of intractable patients that do not benefit from local injections and conventional procedures. Moreover, treatment of occipital neuralgia is sometimes challenging. More invasive procedures, such as C2 gangliotomy, C2 ganglionectomy, C2 to C3 rhizotomy, C2 to C3 root decompression, neurectomy, and neurolysis with or without sectioning of the inferior oblique muscle, are now rarely performed for medically refractory patients. Recently, a few reports have described positive results following peripheral nerve stimulation of the greater or lesser occipital nerve. Although this procedure is less invasive, the significance of the results is hampered by the small sample size and the lack of long-term data. Clinicians should always remember that destructive procedures carry grave risks: once an anatomic structure is destroyed, it cannot be easily recovered, if at all, and with any destructive procedure there is always the risk of the development of painful neuroma or causalgia, conditions that may be even harder to control than the original complaint.

Neuropathic Pain Model of Peripheral Neuropathies Mediated by Mutations of Glycyl-tRNA Synthetase

Charcot-Marie-Tooth disease (CMT) is the most common inherited motor and sensory neuropathy. Previous studies have found that, according to CMT patients, neuropathic pain is an occasional symptom of CMT. However, neuropathic pain is not considered to be a significant symptom associated with CMT and, as a result, no studies have investigated the pathophysiology underlying neuropathic pain in this disorder. Thus, the first animal model of neuropathic pain was developed by our laboratory using an adenovirus vector system to study neuropathic pain in CMT. To this end, glycyl-tRNA synthetase (GARS) fusion proteins with a FLAG-tag (wild type [WT], L129P and G240R mutants) were expressed in spinal cord and dorsal root ganglion (DRG) neurons using adenovirus vectors. It is known that GARS mutants induce GARS axonopathies, including CMT type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V). Additionally, the morphological phenotypes of neuropathic pain in this animal model of GARS-induced pain were assessed using several possible markers of pain (Iba1, pERK1/2) or a marker of injured neurons (ATF3). These results suggest that this animal model of CMT using an adenovirus may provide information regarding CMT as well as a useful strategy for the treatment of neuropathic pain.

Neuropathic Pain Model of Peripheral Neuropathies Mediated by Mutations of Glycyl-tRNA Synthetase

Charcot-Marie-Tooth disease (CMT) is the most common inherited motor and sensory neuropathy. Previous studies have found that, according to CMT patients, neuropathic pain is an occasional symptom of CMT. However, neuropathic pain is not considered to be a significant symptom associated with CMT and, as a result, no studies have investigated the pathophysiology underlying neuropathic pain in this disorder. Thus, the first animal model of neuropathic pain was developed by our laboratory using an adenovirus vector system to study neuropathic pain in CMT. To this end, glycyl-tRNA synthetase (GARS) fusion proteins with a FLAG-tag (wild type [WT], L129P and G240R mutants) were expressed in spinal cord and dorsal root ganglion (DRG) neurons using adenovirus vectors. It is known that GARS mutants induce GARS axonopathies, including CMT type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V). Additionally, the morphological phenotypes of neuropathic pain in this animal model of GARS-induced pain were assessed using several possible markers of pain (Iba1, pERK1/2) or a marker of injured neurons (ATF3). These results suggest that this animal model of CMT using an adenovirus may provide information regarding CMT as well as a useful strategy for the treatment of neuropathic pain.

Dolor neuropático (Parte I): actualización de su definición, mecanismos y diagnóstico / Neuropathic pain (Part I): an update on its definition, mechanisms and diagnosis

El diagnóstico adecuado del dolor neuropático ha sido y continúa siendo motivo de intenso debate. De hecho, en la actualidad no existen pruebas contundentes para el diagnóstico de este tipo de dolor; dicho diagnóstico suele ser eminentemente clínico. Más aún, en Argentina aún se carece de guías en el idioma castellano con algoritmos que encaminen hacia soluciones de diagnóstico y tratamiento de dolor neuropático. En la presente revisión, y basàndonos en los esfuerzos recientes de la comunidad internacional para la creación de criterios diagnósticos que permitan la correcta identificación de esta patología debilitante, nos hemos propuesto los siguientes objetivos: 1) ofrecer una visión actualizada del dolor neuropático, su definición, características clínicas y epidemiología, así como la delineación de sus potenciales mecanismos; 2) sugerir estrategias y criterios que contribuyan a un adecuado diagnóstico de los pacientes con dolor neuropático; 3) facilitar la selección de pacientes para el diseño eficaz de ensayos clínicos, y 4) dar el primer paso para la apertura de nuevos canales de comunicación entre médicos clínicos e investigadores clínicos y básicos dedicados al estudio del dolor.

The correct diagnosis of neurophatic pain remains a reason for intense debate. In fact, definitive proof for the diagnosis of this type of pain is still scarce; its identification is mostly of clinical nature. Moreover, guides in Spanish with algorithms orienting the diagnosis and treatment of neuropathic pain are unavailable in Argentina. In the present review, and based on recent efforts of the international community for the creation of a diagnostic criteria that allow the correct identification of neuropathic pain, we have focused in the followings objectives: 1) to offer an updated view of neuropathic pain, its definition, clinical manifestations and epidemiology, as well as the outlining of its potential mechanisms; 2) to suggest strategies and criteria thay may contribute to an adequate diagnosis of patients with neuropathic pain; 3) to facilitate the selection of patients for the design of clinical essays, and 4) to take the first step for the interaction and communication between physicians, and clinical and basic scientist involved in the study of pain.

Validation of a Brazilian quantitative sensory testing (QST) device for the diagnosis of small fiber neuropathies / Validação de um aparelho brasileiro de teste de quantificação sensitiva brasileiro para o diagnóstico de neuropatia de fibras finas

Quantitative sensory testing (QST) is defined as the determination of thresholds for sensory perception under controlled stimulus. Our aim was to validate a new QST device for Brazilian sample. In 20 healthy adults, thermoalgesic thresholds were assessed using a QST prototype (Heat Pain Stimulator-1.1.10; Brazil). A 30 × 30 mm² thermode with a 1°C/s stimulus change rate were applied. Thresholds of three consecutive stimuli were averaged in two different sessions separated by at least two weeks. Additionally long thermal heat pain stimulus was performed. To evaluate the consistency of our method we also analyzed 11 patients with small fiber neuropathy. Results showed good reproducibility of thermal perception thresholds in normal individuals and plausible abnormal thresholds in patients. We conclude that our QST device is reliable when analyzing the nociceptive pathway in controls and patients.

Teste de quantificação sensitiva (TQS) significa determinação de limiares de percepção sensitiva frente a um estímulo de intensidade controlada. Nosso objetivo foi validar um novo equipamento de TQS adaptado à população brasileira. Em 20 adultos saudáveis, limiares termoalgésicos foram avaliados, utilizando um aparelho protótipo do TQS (Heat Pain Stimulator-1.1.10; Brazil). Foi utilizado um termodo de 30 × 30 mm², com estímulo térmico de 1°C/s. A média dos limiares de três estímulos consecutivos foi obtida em duas sessões diferentes, separadas por pelo menos 2 semanas. Adicionalmente, foram aplicados estímulos térmicos dolorosos de longa duração. Para avaliar a consistência do nosso método, foram também analisados 11 pacientes com neuropatia de fibras finas. Os resultados mostraram boa reprodutibilidade dos limiares de percepção nos indivíduos saudáveis, assim como limiares anormais nos pacientes. Em conclusão, nosso aparelho de TQS apresentou boa confiabilidade ao analisar a via nociceptiva de controles e pacientes.

Guía para definición y manejo del dolor neuropático localizado (DNL): consenso chileno / Guidelines for definition and management of localized neuropathic pain (LNP): Chilean consensus

En los últimos años, diversas Guías para el Manejo del Dolor Neuropático (DN) se han elaborado por grupos de expertos en Dolor. La Asociación Chilena para el Estudio del Dolor (ACHED), representada por diversos especialistas, se reunió los días 5 y6 de agosto para elaborar la “Guía para Definición y Manejo del Dolor Neuropático Localizado (DNL): Consenso Chileno”.Utilizando el Método Delphi, se establecieron consensos con respecto a la entidad Dolor Neuropático Localizado (DNL), tanto en su Definición, Diagnóstico, Manejo Farmacológico y No Farmacológico, constituyendo de este modo, cuatro (4) grupos de trabajo; se establecieron asimismo comisiones para Dolor Pediátrico y Procedimientos Intervencionistas. Los principales resultados permiten contar con una definición clara de DNL, innovaciones en su diagnóstico, algoritmos sencillos para su manejo y recomendaciones no farmacológicas de importancia. Esta Guía para la Definición, Diagnóstico y Manejo del DNL será una herramienta de mucha utilidad en la práctica clínica, especialmente para los médicos generales y para la conformación de equipos multidisciplinarios para la mejor atención de los pacientes de DNL. El Consenso, luego de revisar evidencias y por la experiencia clínica de los expertos, recomiendan las terapias tópicas como las más indicadas en tratamiento del DNL.

In recent years, several Guidelines for the Management of Neuropathic Pain (NP) have been developed by groups that specialize in pain. The Chilean Association for the Study of Pain (ACHED), represented by different specialists, met on the5th and 6th of August to develop the Guidelines for Definition and Management of Localized Neuropathic Pain (LNP): Chilean Consensus”. Using the Delphi method, a series of consensus have been established regarding the Localized Neuropathic Pain (LNP) entity, both in its definition, diagnosis, pharmacological and non pharmacological management, thus constituting four (4) workgroups; committees were also established for pediatric pain and interventional procedures. The main results allow us to have a clear definition of LPN, innovations in its diagnosis, simple algorithms for its management and important non-pharmacological recommendations. The Guidelines for Definition and Management of the LNP will be a very useful tool in clinical practice, especially for general practitioners and for the formation of multidisciplinary teams to improve healthcare for LNP patients. The Consensus, after reviewing evidence and clinical experience, recommends topical therapies as the most appropriate treatment in LPN.

Neuropathic pain characteristics in patients from Curitiba (Brazil) with spinal cord injury / Dor neuropática em pessoas com lesão medular residentes em Curitiba (Brasil)

This was a descriptive cross-sectional study on patients with spinal cord injuries living in Curitiba, Paraná, Brazil. The aim was to evaluate the pain characteristics among such patients seen at referral care centers for spinal cord injury patients in Curitiba. A total of 109 adults with spinal cord injury in this city were evaluated regarding the presence of pain, especially neuropathic pain. Neuropathic pain was evaluated using the DN4 questionnaire, a universal instrument that has been translated and validated for Portuguese. A visual analog scale (VAS) was used to evaluate the intensity of pain. The prevalence of pain among these 109 patients was 31.2 percent (34 patients). The nociceptive pain presented was classified as musculoskeletal pain (nine patients), visceral pain (four patients) and mixed pain (one patient), thus totaling 14 patients (12.8 percent). Another 20 patients (18.3 percent) showed symptoms of neuropathic pain and fulfilled the criteria for neuropathic pain with scores greater than 4 out 10 in the DN4 questionnaire. Regarding the characteristics of the patients with neuropathic pain, most of them were male, younger than 40 years of age and paraplegic with incomplete lesions. They had become injured from 1 to more than 5 years earlier. The predominant etiology was gunshot wounds, and the intensity of their pain was high, with VAS scores greater than 5. This study partially corroborates other studies conducted on this subject. Studies of this type are important for understanding the profile of these patients, for the purpose of designing strategies for their rehabilitation, with a focus on the appropriate treatment and management of pain.

Estudo transversal descritivo em pacientes com lesão medular que residem em Curitiba, Paraná, Brasil. O objetivo foi avaliar as características da dor em pacientes com lesão medular acompanhados em Centros de Reabilitação de referência na cidade. Os sujeitos envolvidos na pesquisa foram 109 pacientes adultos com lesão medular. Foi avaliada a presença de dor, principalmente dor neuropática, mediante aplicação do Questionário DN4, um instrumento universal traduzido e validado para o português. A Escala Visual Analógica (EVA) também foi usada para avaliar a intensidade da dor. A prevalência de dor nos 109 pacientes avaliados foi de 31,2 por cento, ou seja, 34 pacientes. Destes, nove apresentaram dor nociceptiva classificada como músculo-esquelética, quatro dor visceral e um paciente apresentou dor mista, totalizando 14 pacientes (12,8 por cento). Além disso, 20 pacientes (18,3 por cento) apresentaram dor neuropática, cumprindo os critérios para este tipo de dor com uma contagem superior a 4/10 para o DN4. Sobre as características dos pacientes com dor neuropática, a maioria era do sexo masculino, abaixo de 40 anos, paraplégico com lesão incompleta e tempo de evolução entre um e cinco anos de lesão. A etiologia predominante foi perfuração por arma de fogo e a intensidade da dor era severa, com EVA superior a cinco. Este estudo confirma parcialmente outros estudos publicados sobre o tema. Pesquisas deste tipo são importantes para entender o perfil destes pacientes com a finalidade de estabelecer estratégias para uma reabilitação com foco no tratamento e manejo adequado da dor.

Sintomas depressivos e qualidade de vida em pacientes diabéticos tipo 2 com polineuropatia distal diabética / Depressive symptoms and quality of life in type 2 diabetic patients with diabetic distal polyneuropathy

OBJETIVO: Avaliar o impacto dos sintomas depressivos e da dor neuropática na qualidade de vida (QV) de pacientes diabéticos com polineuropatia distal diabética (PNDD). MÉTODOS: Foram avaliados 204 pacientes com diabetes melito tipo 2. O diagnóstico de PNDD foi realizado por meio do Escore de Sintomas Neuropáticos e Escore de Comprometimento Neuropático. A gravidade da dor neuropática foi avaliada por meio da Escala Visual Analógica (EVA); os sintomas depressivos, por meio do Inventário Beck de Depressão (IBD); a QV, com o World Health Organization Quality of Life abreviado (WHOQOL-bref). RESULTADOS: Pacientes com PNDD apresentaram escores mais altos no IBD (12,6 ± 7,2 versus 9,9 ± 7,3; p = 0,018) e no EVA (5,0 ± 2,4 versus 2,6 ± 2,9, p < 0,001). Em relação à QV, apresentaram escores mais baixos no domínio físico (52,8 ± 15,5 versus 59,2 ± 17,0; p = 0,027) e ambiental (56,6 ± 12,3 versus 59,6 ± 13,6; p = 0,045). CONCLUSÕES: Pacientes diabéticos com PNDD apresentam pior QV nos domínios físico e ambiental do WHOQOL-bref, provavelmente devido à maior sintomatologia depressiva e gravidade de dor.

OBJECTIVE: To investigate the impact of depressive symptoms and neuropathic pain in the quality of life (QL) of diabetic patients with diabetic distal polyneuropathy (DDP). METHODS: Two hundred and four patients with type 2 diabetes mellitus were evaluated. The diagnosis of DDP was achieved using the Neuropathy Disability Score and Neuropathy Symptom Score questionnaires. The severity of neuropathic pain was assessed by means of a Visual Analogue Scale (VAS); the severity of depression, by means of the Beck Depression Inventory (BDI); and QL was assessed by means of the World Health Organization Quality of Life Instrument-bref (WHOQOLbref). RESULTS: Patients with DDP presented significant higher scores in BDI (12.6 ± 7.2 versus 9.9 ± 7.3; p = 0.018) and in VAS (5.0 ± 2.4 versus 2.6 ± 2.9; p < 0.001). They also presented significant lower scores in the physical (52.8 ± 15.5 versus 59.2 ± 17.0; p = 0.027) and environmental domains (56.6 ± 12.3 versus 59.6 ± 13.6; p = 0,045). CONCLUSIONS: Diabetic patients with DDP presented a worse QL in the physical and environmental domains of the WHOQOL-bref, probably due to more depressive symptoms and the severity of pain.

What do general neurologists need to know about neuropathic pain? / O que os neurologistas gerais devem saber sobre dor neuropática?

Neuropathic pain (NP) is defined as pain caused by lesion or dysfunction of the somatosensory system, as a result of abnormal activation of the nociceptive pathway (small fibers and spinothalamic tracts). The most common causes of this syndrome are the following: diabetes, post-herpetic neuralgia, trigeminal neuralgia, stroke, multiple sclerosis, spinal cord injury, HIV infection, cancer. In the last few years, the NP has been receiving special attention for two main reasons: (1) therapeutical refractoriness of a variety of pain syndromes with predominant neuropathic characteristics and (2) the development of diagnostic tools for neuropathic pain complaints. The present review article provides relevant information on the understanding and recognition of NP, as well as evidence-based therapeutic approaches.

A dor neuropática (DN) é definida como dor causada por lesão ou disfunção do sistema somatossensitivo, como resultado da ativação anormal da via nociceptiva (fibras de pequeno calibre e trato espinotalâmico). As principais causas desta síndrome são: diabetes, neuralgia pós-herpética, neuralgia trigeminal, acidente vascular encefálico, esclerose múltipla, trauma raquimedular, infecção por HIV, câncer. Nos últimos anos, a DN vem recebendo especial atenção por dois motivos principais: (1) refratariedade terapêutica de várias síndromes dolorosas com componentes neuropáticos predominantes e (2) desenvolvimento de ferramentas diagnósticas para o reconhecimento deste tipo de dor. O presente artigo de revisão fornece informações relevantes para o entendimento e reconhecimento da DN, bem como de abordagens terapêuticas baseadas em evidência.

Study of neuropathic pain among patients with chronic low back pain

Chronic low back pain refers to pain, muscle tension, or stiffness localized below the costal margin and above the inferior gluteal fold [with or without leg pain] of 3 months or more in duration. Identify the neuropathic pain among patients with chronic low back pain through application of LANSS scale, identify the different aetiogenesis, study the associated medical conditions and socio-demographic features of neuropathic pain among patients with chronic low back pain. The study was carried out at Neurology department of AL Azhar University Hospitals, between Nov., 2006 and Dec., 2008. Sixty consecutive patients were included in the study. All of them suffered from chronic low back pain of 3 months or more in duration. They were subjected to the following: Complete history taking, full general and neurological examination with application of LANSS scale for detection of the neuropathic group. Routine laboratory investigation. Lumbosacral Plain x-ray anteroposterior, lateral and oblique views. Neurophysiological examination [NCS, EMG, SSEP] for the neuropathic group. Lumbosacral MRI for the neuropathic group. Ten normal controls were selected to match patient of neuropathic group in age, height and sex, they were subjected only for neurophysiologic examination [NCS and EMG]. The most prominent clinical features of neuropathic pain among patients presented mainly with neuropathic LBP where paroxysmal pain, dysesthesia, allodynia and altered pin prick threshold. The MRI has highly sensitivity for identification of disc prolapse. The needle electrode examination [NEE] has highly specificity for identification of radicuolopathy. The neuropathic pain is a contributing factor among patients presented with chronic low back pain and was attributed to many factors in our study like compressive radiculopathy, radiculopathy, nonspecific and discogenic cause. LANSS Scale is good bedside diagnostic tool that evaluate the presence of a neuropathic component of the low back pain

Cross-cultural adaptation to the Thai language of the neuropathic pain diagnostic questionnaire (DN4).

OBJECTIVE: To cross-culturally adapt the neuropathic pain diagnostic questionnaire (DN4) to Thai language MATERIAL AND METHOD: Phase 1: Forward and backward translation followed by assessment of semantic equivalence. Phase 2: Testing of the questionnaire in 30 neuropathic pain patients who were seen and diagnosed by experts, followed by modifications to produce a final version. RESULTS: All the Thai translated pain descriptors except 'tingling' got high percentages of understanding among neuropathic pain patients in the first round of testing. After some adaptation of the Thai word for 'tingling' had been made, the new translated word was retested, and all subjects doing the retest understood the word very well. CONCLUSION: The Thai DN4 questionnaire was systematically translated and validated. This offers a simple Thai neuropathic pain diagnostic tool for clinical use.

A survey of patients with neuropathic pain at Siriraj Pain Clinic.

OBJECTIVE: To examine the profile and treatment pattern of patients with neuropathic pain attending Siriraj Pain Clinic. MATERIAL AND METHOD: A 2-year retrospective study of the prevalence of neuropathic pain, characteristics of the patients and the use of medical treatment. Records of all the patients that attended Siriraj Pain Clinic from September 1, 2002 until September 30, 2004 were reviewed. RESULTS: One thousand three hundred and thirty patients' records were reviewed. Five hundred and three patients were diagnosed as having neuropathic pain. The prevalence of neuropathic pain at Siriraj Pain Clinic during the survey period was 37.8%. The average age of neuropathic pain patients was 54 years. The most common type of neuropathic pain was peripheral type, nerve compression in particular. The most common concomitant illness was malignant tumor. The majority of patients (71.8%) had one pain location and the most common site was the lower extremity. The main descriptions of neuropathic pain were radiating, electric shock-like, burning, numbing and shooting. Oral medication was the most common method (79%) of pain-relief treatment. Almost all of the patients (93%) had received more than one type of oral medication. The most commonly used medicine was TCA (77.1%), followed by gabapentin (35%), carbamazepine (34%) and tramadol (24.3%). Most of the pain-relief medicines prescribed at this clinic were under the recommended doses for the treatment of neuropathic pain. CONCLUSION: Characteristics and treatment patterns of neuropathic pain at Siriraj Pain Clinic are similar to those seen in other pain clinics elsewhere in the world. The high prevalence of neuropathic pain in the clinic indicates that this type of pain syndrome is increasingly critical to our clinical practice. More educational programs on neuropathic pain and management are needed for Thai healthcare professionals.